These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 33218331)

  • 1. The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy.
    Kagami T; Yamade M; Suzuki T; Uotani T; Tani S; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Baba S; Sugimura H; Murai J; Pommier Y; Furuta T
    BMC Cancer; 2020 Nov; 20(1):1123. PubMed ID: 33218331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Favorable versus unfavorable prognostic groups by post-chemoradiation FDG-PET imaging in node-positive esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
    Yap WK; Chang YC; Hsieh CH; Chao YK; Chen CC; Shih MC; Hung TM
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):689-698. PubMed ID: 29188300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Murine double minute 2 predicts response of advanced esophageal squamous cell carcinoma to definitive chemoradiotherapy.
    Okamoto H; Fujishima F; Kamei T; Nakamura Y; Ozawa Y; Miyata G; Nakano T; Katsura K; Abe S; Taniyama Y; Sakurai T; Teshima J; Hikage M; Sasano H; Ohuchi N
    BMC Cancer; 2015 Mar; 15():208. PubMed ID: 25880782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of multimodal therapy combining definitive chemoradiotherapy and salvage surgery for T4 esophageal squamous cell carcinoma.
    Sugawara K; Yagi K; Okumura Y; Nishida M; Aikou S; Yamashita H; Yamashita H; Seto Y
    Int J Clin Oncol; 2020 Apr; 25(4):552-560. PubMed ID: 31828451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study.
    Kawakami T; Tsushima T; Omae K; Ogawa H; Shirasu H; Kito Y; Yoshida Y; Hamauchi S; Todaka A; Machida N; Yokota T; Yamazaki K; Fukutomi A; Onozawa Y; Yasui H
    BMC Cancer; 2018 May; 18(1):573. PubMed ID: 29776344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of consolidation chemotherapy following definitive chemoradiotherapy in patients with esophageal squamous cell cancer.
    Wu SX; Li XY; Xu HY; Xu QN; Luo HS; Du ZS; Huang HC; Wu ZY
    Sci Rep; 2017 Dec; 7(1):16870. PubMed ID: 29203855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YAP1 amplification as a prognostic factor of definitive chemoradiotherapy in nonsurgical esophageal squamous cell carcinoma.
    Dai H; Shao YW; Tong X; Wu X; Pang J; Feng A; Yang Z
    Cancer Med; 2020 Mar; 9(5):1628-1637. PubMed ID: 31851786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endoscopic findings suggestive of a high risk of non-radical cure after definitive chemoradiotherapy for cT1bN0M0 esophageal squamous cell carcinoma.
    Fukuhara M; Urabe Y; Oka S; Ishibashi K; Konishi H; Mizuno J; Tanaka H; Tsuboi A; Yamashita K; Hiyama Y; Takigawa H; Kotachi T; Yuge R; Hayashi R; Nishibuchi I; Murakami Y; Nagata Y; Tanaka S
    Esophagus; 2023 Jul; 20(3):541-547. PubMed ID: 37027046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy.
    Taniyama D; Sakamoto N; Takashima T; Takeda M; Pham QT; Ukai S; Maruyama R; Harada K; Babasaki T; Sekino Y; Hayashi T; Sentani K; Pommier Y; Murai J; Yasui W
    Cancer Sci; 2022 Feb; 113(2):784-795. PubMed ID: 34808009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schlafen family member 11 indicates favorable prognosis of patients with head and neck cancer following platinum-based chemoradiotherapy.
    Hamada S; Kano S; Murai J; Suzuki T; Tsushima N; Mizumachi T; Suzuki M; Takashima T; Taniyama D; Sakamoto N; Fujioka Y; Ohba Y; Homma A
    Front Oncol; 2022; 12():978875. PubMed ID: 36741698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoradiotherapy With or Without Surgery for Esophageal Squamous Cancer According to Hospital Volume.
    Duarte MBO; Pereira EB; Lopes LR; Andreollo NA; Carvalheira JBC
    JCO Glob Oncol; 2020 Jun; 6():828-836. PubMed ID: 32552112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
    Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
    Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma.
    Jeong H; Im HS; Bang Y; Kim YH; Kim HR; Lee HJ; Jung HY; Lee GH; Song HJ; Kim DH; Choi KD; Lee JH; Ahn JY; Na HK; Ryu JS; Kang J; Kim SB; Kim JH; Park SR
    Cancer Med; 2021 Mar; 10(5):1745-1758. PubMed ID: 33590710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer.
    Okamoto H; Taniyama Y; Sakurai T; Heishi T; Teshima J; Sato C; Maruyama S; Ito K; Onodera Y; Konno-Kumagai T; Ishida H; Kamei T
    Esophagus; 2018 Oct; 15(4):281-285. PubMed ID: 29948480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of transthoracic esophagectomy with definitive chemoradiotherapy as initial treatment for patients with esophageal squamous cell carcinoma who could tolerate transthoracic esophagectomy.
    Matsuda S; Tsubosa Y; Niihara M; Sato H; Takebayashi K; Kawamorita K; Mori K; Tsushima T; Yokota T; Ogawa H; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Ann Surg Oncol; 2015; 22(6):1866-73. PubMed ID: 25564176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of blood oxygenation level-dependent magnetic resonance imaging in early evaluation of the response and prognosis of esophageal squamous cell carcinoma treated with definitive chemoradiotherapy: a preliminary study.
    Zheng H; Zhang H; Zhu Y; Wei X; Liu S; Ren W
    BMC Med Imaging; 2024 Jan; 24(1):18. PubMed ID: 38216885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGF5 methylation is a sensitivity marker of esophageal squamous cell carcinoma to definitive chemoradiotherapy.
    Iwabu J; Yamashita S; Takeshima H; Kishino T; Takahashi T; Oda I; Koyanagi K; Igaki H; Tachimori Y; Daiko H; Nakazato H; Nishiyama K; Lee YC; Hanazaki K; Ushijima T
    Sci Rep; 2019 Sep; 9(1):13347. PubMed ID: 31527639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of definitive chemoradiotherapy versus surgery as initial treatments for potentially resectable esophageal carcinoma.
    Ma MW; Gao XS; Gu XB; Xie M; Cui M; Zhang M; Liu L; Yin H; Chen LQ
    World J Surg Oncol; 2018 Aug; 16(1):172. PubMed ID: 30119684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined modalities of magnetic resonance imaging, endoscopy and computed tomography in the evaluation of tumor responses to definitive chemoradiotherapy in esophageal squamous cell carcinoma.
    Qiu B; Wang D; Yang H; Xie W; Liang Y; Cai P; Chen Z; Liu M; Fu J; Xie C; Liu H
    Radiother Oncol; 2016 Nov; 121(2):239-245. PubMed ID: 27793445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
    Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
    Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.